论文部分内容阅读
Aims: To evaluate the efficacy and safety of low-dose (2 mg in 0.05 ml) intraocular triamcinolone injection for patients with uveitis-related cystoidmacular oedema and/or intractable intraocular inflammation. Patients and methods: Retrospective clinical case series. Results: Cystoid macular oedema was eliminated in 24/30 eyes (80%). Intractable intraocular inflammation was eliminated in 4/8 eyes (50%). Snellen visual acuity was improved by two lines ormore after 14/36 injections (38.9%). Intraocular pressure rose to above 21mmHg after 8/36 injections (22%). There were no major complications. Conclusions: Low-dose (2 mg in 0.05 ml) intraocular triamcinolone acetonide injection is safe and effective for the management of refractory uveiticmacular oedema. Its usefulness in controlling inflammation alone is questionable.
Aims: To evaluate the efficacy and safety of low-dose (2 mg in 0.05 ml) intraocular triamcinolone injection for patients with uveitis-related cystoidmacular oedema and / or intractable intraocular inflammation. Patients and methods: Retrospective clinical case series. Results: Cystoid macular Intolerable intraocular inflammation was eliminated in 4/8 eyes (50%). Snellen visual acuity was improved by two lines ormore after 14/36 injections (38.9%). Intraocular pressure rose to be 21 mmHg after 8/36 injections (22%). There were no major complications. Conclusions: Low-dose (2 mg in 0.05 ml) intraocular triamcinolone acetonide injection is safe and effective for the management of refractory uveitic maccular oedema. Its usefulness in controlling inflammation alone is questionable